Paper Details 
Original Abstract of the Article :
Gonadotropin-releasing hormone agonists (GnRHa) have been widely used for decades to treat patients with central precocious puberty (CPP). Several studies have investigated changes in body composition in patients with CPP following GnRHa treatment, but the results are inconsistent. The aim of this s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s12020-016-1023-5

データ提供:米国国立医学図書館(NLM)

Investigating BMI Changes During GnRHa Treatment for Puberty

Precocious puberty, the early onset of puberty, can have a significant impact on a child's physical and emotional development. This study examines the changes in body mass index (BMI) in children treated with gonadotropin-releasing hormone agonists (GnRHa) for central precocious puberty (CPP) and early puberty. The authors analyzed data from 383 girls who received depot leuprolide acetate treatment for at least two years, investigating the impact of BMI on treatment outcomes.

Navigating the Landscape of Puberty Treatment

The study reveals that BMI changes during GnRHa treatment vary depending on the child's initial BMI status. While BMI increased significantly in normal-weight children, it remained stable in overweight and obese children. This finding highlights the importance of considering the individual child's BMI status when evaluating treatment outcomes.

A Closer Look at the Effects of GnRHa Treatment

This research provides valuable insights into the potential impact of GnRHa treatment on BMI in children with CPP and early puberty. It underscores the need for careful monitoring of BMI changes during treatment and for tailoring treatment strategies to address individual patient needs. This is a valuable contribution to the ongoing research on managing puberty disorders, offering a deeper understanding of the complex interplay between treatment, BMI, and overall health outcomes.

Dr.Camel's Conclusion

This study investigates the changes in body mass index during GnRHa treatment for central precocious puberty and early puberty. The research highlights the importance of considering the individual child's BMI status when evaluating treatment outcomes and underscores the need for careful monitoring of BMI changes during treatment. This is a valuable contribution to the ongoing research on managing puberty disorders, offering a deeper understanding of the complex interplay between treatment, BMI, and overall health outcomes.

Date :
  1. Date Completed 2017-07-07
  2. Date Revised 2019-02-21
Further Info :

Pubmed ID

27444748

DOI: Digital Object Identifier

10.1007/s12020-016-1023-5

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.